Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.

Sarah McCarronBrooke BathonDonna M ConlonDeepti AbbeyDaniel J RaderKaterina GawronskiChristopher D BrownKim M OlthoffAbraham ShakedTobias D Raabe

Published in: Hepatology (Baltimore, Md.) (2021)

Expansion of primary liver stem cells/organoids derived directly from irreversibly damaged liver from patients with NASH opens up experimental avenues for personalized disease modeling and drug development that has the potential to slow human NASH progression and to counteract NASH-related SARS-CoV-2 effects.

Keyphrases

stem cells
sars cov
induced pluripotent stem cells
endothelial cells
mesenchymal stem cells
bone marrow
climate change
cell therapy